IBB
HealthcareiShares Biotechnology ETF
iShares · Tracks NYSE Biotechnology Index · Inception Feb 5, 2001
Composite score
Based on a 0.44% expense ratio.
Based on $9.09B in net assets.
Top-10 holdings represent 54.7% of net assets.
Healthcare base · ETF wrapper · 0.22% TTM yield.
The composite is a weighted average of the four core sub-scores above (cost, tax efficiency, liquidity, concentration). Missing sub-scores fall back to the per-category median when the category has at least 50% data coverage, so funds without (e.g.) parsed N-PORT holdings aren't accidentally boosted by renormalization. Tracking quality is shown where computable but isn't currently part of the composite weighting. See methodology for formulas, the tracking-quality partial-coverage rationale, and the dimensions we deliberately don't score (methodology v0.5.1).
Use IBB in our tools
Tool · Cost
Compare IBB's fee against another fund
Compounds the 0.44% expense ratio against a peer over decades.
Tool · Overlap
Compare IBB's holdings with peers
Pairwise holdings heatmap, pre-loaded with similar Healthcare funds.
Tool · TLH
Find a tax-loss harvesting partner for IBB
Ranks every catalog fund by holdings overlap, flags wash-sale risk.
Tool · Placement
Where should this fund live across your accounts?
Asset-location optimizer — places each fund in taxable / tax-deferred / Roth.
Top holdings
| # | Holding | Weight |
|---|---|---|
| 1 | BlackRock Funds III | 9.66% |
| 2 | Gilead Sciences, Inc. | 7.75% |
| 3 | Amgen, Inc. | 7.51% |
| 4 | Vertex Pharmaceuticals, Inc. | 7.44% |
| 5 | Regeneron Pharmaceuticals, Inc. | 7.21% |
| 6 | Alnylam Pharmaceuticals, Inc. | 3.99% |
| 7 | Insmed, Inc. | 3.20% |
| 8 | Argenx SE | 3.07% |
| 9 | Biogen, Inc. | 2.46% |
| 10 | Natera, Inc. | 2.41% |
Compare IBB with another fund
Or skim the closest-overlap funds below.
Similar ETFs by holdings overlap
Open IBB at a brokerage
Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.